BHV-1450
/ Biohaven
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 12, 2026
BHV-1450, an Ig-G4 selective MODE degrader, mitigates anti-Dsg3-mediated skin damage implicated in Pemphigus vulgaris
(AAD 2026)
- "Treatment with BHV-1450, both prophylactically and therapeutically, demonstrated efficacy in rescuing the disease phenotype. BHV-1450 showed potency in vitro and in vivo, as well as efficacy in a disease phenotype in vivo, and was optimized for the treatment of IgG4-AIDs, including PV."
CNS Disorders • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Myasthenia Gravis • Pemphigus Vulgaris • Thrombocytopenic Purpura • ASGR • MUC4
1 to 1
Of
1
Go to page
1